32 results on '"Sadones J"'
Search Results
2. SO-26 Identification and quantification of the microbiome in colorectal cancer metastases
3. SO-26 Identification and quantification of the microbiome in colorectal cancer metastases
4. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
5. 578P Tissue-resident microbiota characterization in colorectal cancer metastases
6. Phase II study of sunitinib malate in patients with recurrent high-grade glioma
7. The Larval Gills of the Odonata
8. SUNITINIB MALATE AS A SINGLE AGENT OR COMBINED WITH LOMUSTINE (CCNU) IN PATIENTS WITH RECURRENT, TEMOZOLOMIDE REFRACTORY HIGH-GRADE GLIOMA
9. THE PROGNOSTIC/PREDICTIVE ROLE OF IDH1 GENE MUTATIONS IN PATIENTS TREATED FOR RECURRENT GLIOMA
10. A stratified phase II study of cetuximab for the treatment of recurrent glioblastorna multiforme: Preliminary results
11. Primary leptomeningeal anaplastic oligodendroglioma with a 1p36–19q13 deletion: Report of a unique case successfully treated with Temozolomide
12. Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
13. Phase II study of sunitinib malate in patients with recurrent high-grade glioma
14. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma
15. Phase II trial of sunitinib malate in patients with temozolomide refractory recurrent high-grade glioma
16. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma
17. A multicenter stratified phase II study of cetuximab for the treatment of patients with recurrent high-grade glioma
18. A phase II trial of sunitinib in patients with recurrent high-grade glioma
19. Myxopapillary ependymoma with extensive spinal and intracranial dissemination at diagnosis: an exceptional case report
20. The role of MGMT promotor hypermethylation as a predictive factor for response to temozolomide in recurrent high-grade glioma
21. A stratified phase II study of cetuximab for the treatment of recurrent glioblastoma multiforme: Preliminary results
22. The Larval Gills of the Odonata.
23. Investigation of the EGFR-gene amplification status determined by FISH as a predictive or prognostic marker for patients with recurrent high-grade glioma treated with temozolomide
24. Neuropathological and molecular aspects of low-grade and high-grade gliomas
25. The role of chemotherapy in the treatment of low-grade glioma. A review of the literature
26. MGMT PROMOTER HYPERMETHYLATION AND P53 IMMUNOHISTOCHEMISTRY PREDICT OUTCOME FOLLOWING TEMOZOLOMIDE FOR RECURRENT 1P/19Q NON-DELETED ANAPLASTIC (OLIGO)ASTROCYTOMA
27. miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells.
28. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
29. Correlation between IDH1 gene mutation status and survival of patients treated for recurrent glioma.
30. A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma.
31. The role of chemotherapy in the treatment of low-grade glioma. A review of the literature.
32. Neuropathological and molecular aspects of low-grade and high-grade gliomas.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.